A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

To be considered for this study, you must be at least 18 years old and have a confirmed diagnosis of Stage III Non-Small Cell Lung Cancer that cannot be surgically removed. You should have already completed a standard course of simultaneous chemotherapy and radiation for your lung cancer, and crucially, your cancer must not have worsened during or after this treatment.

Your medical team would also need to check specific details about your cancer, such as certain genetic markers (EGFR and ALK 'wild-type' status) and a protein called PD-L1, from a tumour sample taken before your chemotherapy and radiation. You also need to be generally well enough to participate, with good levels of health as determined by your doctor and normal function of your organs.

There are also some reasons why you might not be able to join. For example, if you have certain other serious health conditions or other cancers that have required treatment recently, or if you experienced severe side effects like lung inflammation (pneumonitis) from your previous radiation treatment. The study also cannot include patients whose cancer progressed during their initial chemotherapy and radiation, or those who received their radiation and chemotherapy at different times.

If you join the study, you would be randomly assigned to one of two treatment groups, meaning neither you nor your doctor would choose which treatment you receive. You would also not know if you are receiving the combination treatment or the comparison treatment (Durvalumab with a placebo). The study involves regular visits for treatments and assessments, which include blood tests, physical examinations, and scans to monitor your health and how the treatment is working.

The duration of your participation would depend on how your body responds to the treatment. You would continue to receive the study treatment for a set period, or until your cancer worsens, or if you experience unacceptable side effects. Throughout the study, you would have close medical supervision, and there would be follow-up appointments after your treatment period ends to continue monitoring your health.